

# Initiation of Warfarin is associated with Decreased Mortality in Patients with Infective Endocarditis: A Population-Based Cohort Study

Teddy Tai Loy Lee<sup>1,2</sup>, Sunny Ching Long Chan<sup>1</sup>, Oscar Hou In Chou MSc<sup>2,3</sup>, Sharen Lee MBChB<sup>2</sup>, Jeffrey Shi Kai Chan MBChB MPH<sup>2</sup>, Tong Liu MD PhD<sup>4</sup>, Carlin Chang MBChB MPhil<sup>5</sup>, Wing Tak Wong PhD<sup>6</sup>, Gregory Y. H. Lip MD<sup>7,8</sup>, Bernard Man Yung Cheung MBBChir PhD<sup>3</sup>, Abraham Ka-Chung Wai MBChB<sup>1</sup>, Gary Tse MD PhD<sup>4,9,10</sup>

1. Department of Emergency Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China
2. Cardiovascular Analytics Group, China-UK Collaboration, Hong Kong, China
3. Division of Clinical Pharmacology, School of Clinical Medicine, The University of Hong Kong Hong Kong, China
4. Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
5. Division of Neurology, Department of Medicine, Queen Mary Hospital and The University of Hong Kong Hong Kong, China
6. State Key Laboratory of Agrobiotechnology (CUHK), School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China
7. Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom
8. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
9. Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, United Kingdom
10. School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China

Correspondence to:

Dr. Abraham Ka-Chung Wai, MBChB, FRCEM, FRCP  
Department of Emergency Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China  
Email: [awai@hku.hk](mailto:awai@hku.hk)

Prof. Gary Tse, MD, PhD, FRCP, FFPH  
Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, United Kingdom  
Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China  
School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China  
Email: [gary.tse@kmms.ac.uk](mailto:gary.tse@kmms.ac.uk)

Word count: 3617

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Abstract

**Importance:** The use of warfarin as an anticoagulant to prevent thromboembolism in patients with infective endocarditis (IE) remains controversial due to potentially increased bleeding risks.

**Objective:** This study compared the risks of ischemic stroke, death and bleeding in patients with IE with and without warfarin use.

**Design:** Prospective cohort study.

**Setting:** Population-based.

**Participants:** Patients aged 18 or older and diagnosed with IE in Hong Kong between January 1<sup>st</sup> 1997 and August 31<sup>st</sup> 2020 were included. Patients with use of any anticoagulant 30 days before IE diagnosis were excluded. Patients initiated on warfarin within 14 days of IE diagnosis and patients without warfarin use were matched for baseline characteristics using 1:1 propensity score matching.

**Exposure:** Warfarin use within 14 days of IE diagnosis.

**Main outcomes and measures:** Patients were followed up to 90 days for the outcomes of ischemic stroke, all-cause mortality, intracranial hemorrhage, and gastrointestinal bleeding. Cox regression was used to determine hazard ratios (HRs) [95% confidence intervals (CIs)] between treatment groups. Fine-Gray competing risk regression with all-cause mortality as the competing event was performed as a sensitivity analysis. In addition to 90-day analyses, landmark analyses were performed at 30 days of follow-up.

**Results:** The matched cohort consisted of 675 warfarin users (57.0% male, age 59±16 years) and 675 warfarin non-users (53.5% male, age 61±19 years). From Cox regression, warfarin users had a 50% decreased 90-day risk in all-cause mortality (HR: 0.50 [0.39-0.65]), without

significantly different 90-day risks of ischemic stroke (HR: 1.04 [0.70-1.53]), intracranial haemorrhage (HR: 1.25 [0.77-2.04]), and gastrointestinal bleeding (HR: 1.04 [0.60-1.78]). Thirty-day landmark analysis showed similar results. Competing risk regression showed significantly higher 30-day cumulative incidence of intracranial haemorrhage in warfarin users (sub-HR: 3.34 [1.34-8.31]), but not at 90-day (sub-HR: 1.63 [0.95-2.81]). Results from Fine-Gray regression were otherwise congruent with those from Cox regression.

**Conclusions and relevance:** In patients with IE, warfarin use initiated within 14 days of IE diagnosis may be associated with significantly decreased risks of mortality but higher risks of intracranial haemorrhage, with similar risks of ischemic stroke and gastrointestinal bleeding, compared with non-use of warfarin with 14 days of IE diagnosis.

78    **Key points**

79    **Question:** Is warfarin, initiated within 14 days of a diagnosis of infective endocarditis (IE),  
80    efficacious and safe?

81    **Findings:** In this propensity score-matched, population-based, prospective cohort study from  
82    Hong Kong, warfarin use within 14 days of IE diagnosis was associated with a 50% decrease  
83    in the risk of all-cause mortality, albeit with higher risk of intracranial haemorrhage, and  
84    without significant differences in the risk of ischaemic stroke and gastrointestinal bleeding.

85    **Meaning:** In patients with IE, warfarin use within 14 days of diagnosis may have mortality  
86    benefits, despite increased risks of intracranial haemorrhage.

87

## 88 **Non-standard Abbreviations and Acronyms**

89 **ACE:** Angiotensin-converting enzyme

90 **CDARS:** Clinical data analysis and reporting system

91 **CI:** Confidence interval

92 **DOAC:** Direct oral anticoagulant

93 **HACEK:** Hemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium  
94 hominis, Eikenella corrodens, Kingella kingae

95 **HR:** Hazard ratio

96 **H2RA:** Histamine type 2 receptor antagonist

97 **ICD-9:** International Classification of Diseases, Ninth Revision

98 **INR:** International normalized ratio

99 **IE:** Infective endocarditis

100 **NSAID:** Nonsteroidal anti-inflammatory drug

101 **OR:** Odds ratio

102 **PPI:** Proton pump inhibitor

103 **SD:** Standard deviation

104 **SHR:** Sub-hazard ratio

105 **SMD:** Standardized mean difference

106 **VR:** Variance ratio

107

## Introduction

Infective endocarditis (IE) is an acute infection of the cardiac endothelium, characterized by adherence of platelets and fibrin to the endocardial wall in response to injury, forming a vegetation inducing cardiac damage and development of thromboembolic complications. Despite being a rare condition with an annual incidence of 3-10 cases per 100,000 people <sup>1,2</sup>, IE is a challenging condition associated with a high mortality and morbidity, with a reported mortality rate of 30% at 30 days <sup>3</sup>. Without proper treatment, further platelet aggregation and microbial proliferation allows IE vegetations to grow in size <sup>4</sup>, subsequently leading to increased risk of septic embolization <sup>5</sup>. Ischemic stroke, a common and disabling neurological complication caused by an embolized vegetation, has a prevalence of 16.9% <sup>6</sup> and is a leading cause of death in IE <sup>7,8</sup>.

Though fibrin constitutes the main component in vegetations <sup>9,10</sup>, the current 2015 European Society of Cardiology guidelines do not suggest IE per se as an indication for initiating anticoagulation <sup>11</sup>. However, preclinical studies have shown that anticoagulant use is associated with reduced vegetation size, bacterial load, and inflammation in IE <sup>12,13</sup> and may have a role in long-term IE prophylaxis <sup>14</sup>. Indeed, the role of anticoagulation therapy in IE management is highly controversial due to the associated bleeding risks. Warfarin is a Vitamin K antagonist which inhibits Vitamin K epoxide production of clotting factors and has previously been used to treat valvular vegetations and as prophylaxis against embolic stroke <sup>15-17</sup>. However, the benefits of prophylaxis must be balanced against bleeding risks, notably intracranial hemorrhage <sup>18</sup>.

Current data on the efficacy and safety of warfarin therapy in IE are limited, and published clinical studies often have a small numbers of patients. Owing to the lack of evidence, surgical treatment and antibiotics remain the preferred option for reducing the risk of ischemic

stroke. Therefore, the present study examined the efficacy in terms of stroke risk reduction, and safety in terms of bleeding risks of warfarin use in a large population-based cohort of patients with IE.

## Methods

This study was been approved by The Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee and The University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board. The need for informed consent was waived owing to the retrospective use of deidentified patient data in this study. Patient data was obtained through the Clinical Data Analysis and Reporting System (CDARS), a territory-wide electronic healthcare database managed by the Hong Kong Hospital Authority, which serves an estimated 90% of the population in Hong Kong. CDARS has previously been used extensively to conduct large population-based studies<sup>19, 20</sup>, including those on anticoagulation use<sup>21, 22</sup>.

### *Study Cohort*

All patients aged 18 or above with a diagnosis of IE who attended any public hospitals between January 1<sup>st</sup>, 1997 to August 31<sup>st</sup>, 2020 were identified from CDARS. The date of first diagnosis of IE was defined as the index date. Patients who received warfarin prescriptions within 14 days since the index date were considered warfarin users. To select new users only, patients who received warfarin or other anticoagulant medications (rivaroxaban, dabigatran, apixaban, edoxaban, enoxaparin, fondaparinux or heparin) within an entry period 30 days prior to the index date were excluded.

### *Outcomes*

To study the efficacy and safety of warfarin use, study outcomes included 90-day risks of embolic stroke and all-cause mortality (efficacy), and intracranial hemorrhage and gastrointestinal bleeding (safety). An *a priori* landmark analysis was done at 30 days to compare the 30-day risks. Details of International Classification of Diseases, Ninth Revision (ICD-9) codes used to define outcomes are described in **Supplementary Table 1**. Outcomes were followed up until the occurrence of outcome, death, or until 90 days after IE diagnosis, whichever earlier.

### *Covariates*

We traced patient records on CDARS prior to the index date and collected patient information including age at index date, sex, comorbidities (hypertension, atrial fibrillation, heart failure, diabetes mellitus, ischemic heart disease, chronic kidney disease, vascular disease), history of valvular replacement, and recent medication use, including drugs related to bleeding risk (ACE inhibitors, angiotensin receptor blockers, beta blockers, nonsteroidal anti-inflammatory drugs [NSAIDs], histamine type 2 receptor antagonists [H2RAs], proton pump inhibitors [PPIs], selective serotonin reuptake inhibitors [SSRIs]), and pathogens identified from blood culture (staphylococci, streptococci, enterococci, HACEK group) taken during IE admission. We also traced the number of patients who received direct oral anticoagulants (DOACs), heparin (fondaparinux, enoxaparin, heparin), and cardiac surgery (ICD-9-CM Procedure codes 35-39) within 14 days since the index date. ICD-9 codes used to identify comorbidities are described in **Supplementary Table 1**.

### *Statistical Analysis*

This study tested the hypothesis that when compared to non-usage, warfarin usage is associated with different risks of efficacy and safety study outcomes of ischemic stroke, all-cause mortality, intracranial hemorrhage and gastrointestinal bleeding. To account for



differences between groups in baseline characteristics due to a lack of randomization, we used propensity score matching on a 1:1 ratio using the nearest-neighbour matching algorithm to match warfarin users with non-users by the aforementioned covariates. A caliper width of 0.2 was chosen as it is considered optimal for propensity score matching<sup>23</sup>. Standardized mean differences (SMD), the differences in means over the pooled standard deviation (SD) assessed balance of categorical covariates; the variance ratio (VR), which is the ratio of variance between the treatment and control groups assessed balance of both categorical and continuous covariates. Characteristics with an SMD of <0.1 or VR between the range of 0.5 and 2.0 were considered balanced. Descriptive statistics were expressed as mean  $\pm$  SD and count (percentage [%]) as appropriate.

Result estimates were expressed in terms of hazard ratios (HRs) with 95% confidence intervals (CIs) using a univariate Cox proportional hazards model. The proportional hazards assumption of the model was tested by performing the Schoenfeld proportionality test; the results indicated that the assumption was met. Kaplan-Meier curves were plotted against the time-to-event, beginning from the date of IE diagnosis stratified by either warfarin use or no warfarin use for the main results, and beginning from the date of warfarin initiation and stratified by either early or late initiation of warfarin for analysis of warfarin timing. The log-rank test was performed to investigate the statistical significance of differences in survival between comparator groups.

An *a priori* subgroup analysis was performed: 90-day risks of the efficacy outcomes in patients who were initiated on warfarin early ( $\leq 7$  days) were compared to those with late initiation (within 8 to 14 days) to explore the effect of initiation timing within warfarin users; in this analysis, the start date of follow-up was defined as the date of warfarin initiation instead of date of IE diagnosis. As there were substantial imbalances between treatment arms in the respective proportions of patients who received cardiac surgery and heparin within 14 days of

the index day, two *post hoc* subgroup analyses were added, where patients who received cardiac surgery and heparin were excluded separately. Furthermore, two *a priori* sensitivity analyses were conducted. First, the period in which warfarin was initiated was restricted from within 14 days to within 7 days of the index date. Second, a competing risk regression was performed for ischaemic stroke, intracranial haemorrhage, and gastrointestinal bleeding using the Fine and Gray sub-distribution model, with all-cause mortality as the competing event, and with sub-hazard ratios (SHRs) and the corresponding 95% CIs as summary statistics. Aalen-Johansen cause-specific cumulative incidence curves were additionally plotted for these outcomes to account for competing risks.

All analyses were conducted using R (version 1.4.1717) or Stata (version 16.1). All p-values were two-tailed and considered statistically significant when  $P < 0.05$ .

## Results

### *Patient characteristics*

The patient flow is shown in **Figure 1**. In total, 7,054 patients with a diagnosis of IE were identified from CDARS. After excluding patients with previous anticoagulant use, under 18 years old, and those with use of warfarin after 14 days since IE diagnosis, the study cohort consisted of 5,477 patients, where 734 patients received warfarin (56.7% male, mean baseline age:  $60 \pm 16$  years old) and 4743 without warfarin use (66.5% male, mean baseline age:  $58 \pm 20$  years old). All patients completed 90-day follow up or had 90-day mortality.

After 1:1 propensity score matching, the final study cohort consisted of 675 warfarin users and 675 without warfarin use. The baseline characteristics of the study population are shown in **Table 1**. A Love plot summarizing covariate balance before and after propensity score matching is shown in **Supplementary Figure 1**. All SMD values were  $< 0.1$  and VR

values within 0.5-2.0, indicating good balance between warfarin users and those without warfarin use; the only exception being age, which had a SMD of 0.13. After matching, 13 (1.9%) warfarin users and 23 (3.4%) patients without warfarin use received DOACs, while 435 (64.4%) warfarin users 68 (10.1%) patients without warfarin use received heparin. 162 (24.0%) warfarin users compared to 59 (8.7%) patients without warfarin use received cardiac surgery within 14 days of IE diagnosis.

The ten most common causes of death were described in **Supplementary Table 2**. The most common causes of death in warfarin users were IE (7.0%), followed by pneumonia (2.2%), sepsis (1.2%), heart failure (0.9%), and rheumatic heart disease (0.6%); while in patients without warfarin use, the most common causes of death were IE (2.5%), followed by pneumonia (1.2%), stroke (0.9%), rheumatic heart disease (0.6%), and intracranial hemorrhage (0.6%). 2 (0.3%) patients without warfarin use and 6 (0.9%) patients with warfarin use died of stroke, while 6 (0.8%) patients without warfarin use and 7 (1.0%) patients with warfarin use died of intracranial, intracerebral or subarachnoid hemorrhage (**Supplementary Table 3**).

#### *Main 90- and 30-day analytic results*

The main analytic results are presented in **Table 2**, and Kaplan-Meier plots are shown in **Figure 2**. While warfarin use was not associated with a significantly different 90-day risk of ischemic stroke (HR: 1.04 [95% CI, 0.70-1.53], log-rank p=0.86), it was associated with a 50% decrease in the 90-day risk of all-cause mortality (HR: 0.50 [0.39-0.65], log-rank p<0.0001). For the safety outcomes, warfarin use was not associated with significantly different 90-day risks of gastrointestinal bleeding (HR 1.04 [0.60-1.78], log-rank p=0.90), although a nonsignificant trend for intracranial hemorrhage (HR: 1.25 [0.77-2.04]; log-rank p=0.37) may be present.

Results of the 30-day landmark analysis for ischemic stroke (HR: 0.87 [0.53-1.43]), all-cause mortality (HR: 0.41 [0.28-0.58]), intracranial hemorrhage (HR: 1.57 [0.80-3.07]) and gastrointestinal bleeding (HR: 0.86 [0.41-1.81]) were consistent with those of the main, 90-day analysis.

#### *Subgroup analysis*

Results of subgroup analyses are shown in **Table 2** as well. In the *a priori* subgroup analysis exploring the effects of the timing of warfarin initiation, warfarin initiation between 8-14 days of IE diagnosis (delayed use; N=152) was not associated with significantly different 90-day risks of ischemic stroke (HR: 1.53 [0.82-2.86]) or all-cause mortality (HR: 1.29 [0.78-2.14]) compared with early use (warfarin initiation within the seven days of IE diagnosis; N=523; **Figure 3**). Landmark analysis at 30 days showed consistent results (**Supplementary Table 4**).

In the first *post hoc* subgroup analysis excluding patients who received heparin within 14 days of IE diagnosis, warfarin use was associated with significantly lower 90-day risk of all-cause mortality (HR: 0.59 [0.40-0.86]), but also significantly higher 90-day risk of intracranial haemorrhage (HR: 2.56 [1.13-5.81]; **Supplementary Figure 2**); the 90-day risk of intracranial haemorrhage and gastrointestinal bleeding were not significantly different between treatment arms. Landmark analysis at 30 days showed largely consistent results, except for the nonsignificant trend in the 30-day risk of intracranial haemorrhage between treatment arms (HR: 2.54 [0.98-6.54]).

In the second *post hoc* subgroup analysis excluding patients who received cardiac surgery within 14 days of IE diagnosis, warfarin use was again associated with significantly lower 90-day risk of all-cause mortality (HR: 0.47 [0.35-0.64]), but also significantly higher 90-day risk of intracranial haemorrhage (HR: 1.89 [1.01-3.53]; **Supplementary Figure 3**); the

90-day risk of intracranial haemorrhage and gastrointestinal bleeding were not significantly different between treatment arms. Landmark analysis at 30 days showed largely consistent results, except the 30-day risk of intracranial haemorrhage was not significantly different between treatment arms (HR: 1.71 [0.78-3.73]).

### *Sensitivity analysis*

Results of sensitivity analyses were summarized in **Table 3**. When only patients with warfarin use within seven days of IE diagnosis were included in the warfarin arm (N=523), warfarin use was associated with significantly lower 90-day risk of all-cause mortality (HR: 0.51 [0.38-0.67]), but not significantly different 90-day risks of ischemic stroke (HR: 0.81 [0.54-1.23]), intracranial hemorrhage (HR: 0.75 [0.45-1.26]), nor gastrointestinal bleeding (HR: 0.56 [0.30-1.03]).

In the Fine and Gray competing risk regression with all-cause mortality as competing events, warfarin users had significantly higher 30-day cumulative incidence of intracranial haemorrhage (SHR 3.34 [1.34-8.31]; **Supplementary Figure 4**), but the 90-day cumulative incidence was not significantly different between groups (SHR 1.63 [0.95-2.81]). The cumulative incidences of ischaemic stroke (**Supplementary Figure 5**) and gastrointestinal bleeding (**Supplementary Figure 6**) were not significantly different between groups at both 30 and 90 days.

## **Discussion**

To the best of the authors' knowledge, this is the first population-based study on warfarin use in IE patients. In this study, warfarin use in patients with IE was associated with a significantly lower risk of mortality, without significantly different risks of ischemic stroke.

However, warfarin use may be associated with significantly higher risk of intracranial haemorrhage, despite a lack of significant differences in the risk of other bleeding events.

The most important finding of this study was that in patients with IE, warfarin use was associated with lower mortality risks at both 30 and 90 days. The reduction of clotting factors and reduced platelet aggregation through warfarin use may slow the local proliferation of vegetation, reducing valvular destruction and the extent of the infection, leading to improved prognosis. Clinically, these properties of warfarin are most leveraged for ischaemic stroke prevention. In this study, however, the mortality benefit observed for warfarin use was clearly not driven by ischaemic stroke risk reduction, as warfarin use was not associated with significantly different risk of ischaemic stroke. This contrasts with two studies focused on left-sided staphylococcus aureus IE, where anticoagulation was found to reduce stroke risk<sup>24, 25</sup>. For example, Rasmussen and colleagues described in a study of 175 IE patients that anticoagulant use, defined as use of either coumadin or high-dose low molecular weight heparin, was associated with a fourfold decrease in stroke risk (adjusted odds ratio [aOR]: 0.27), but most patients who received anticoagulants had prosthetic valves (73%) compared to those without anticoagulant use (8%)<sup>24</sup>. In another cohort study of 587 IE episodes, warfarin use was associated with a lower risk of cerebrovascular complications (aOR: 0.26 [95% CI, 0.07-0.94]), where 38% of patients with warfarin use and 12% patients without warfarin use had atrial fibrillation on admission<sup>25</sup>. Nonetheless, both studies included patients who already had continuous use of anticoagulants prior to IE admission. As patients already on treatment may have stably reached the therapeutic international normalized ratio (INR) range, the baseline risk for stroke of the anticoagulant group may be lower at the time of IE diagnosis. Instead, to ensure a new-user design, we excluded patients with prior use of any anticoagulant within 30 days before IE diagnosis, and balanced the coagulability status of treatment groups by matching

with medications that influence coagulability, which may explain the lack of significant benefit among new users in reducing ischemic stroke risk compared to previous studies.

The mortality benefit may be driven by a reduction in the size of vegetation, as suggested by previous studies<sup>15, 24</sup>. As echocardiography data were not available, this could not be verified in our study. It is also unclear whether effects on the size of vegetation was affected by the causative organism. Another potential driver of the observed associations may be differences in the risks of thromboembolic complications such as septic pulmonary embolism<sup>26</sup>. Septic pulmonary emboli pose high risk to patients as it can cause subsequent respiratory failure requiring mechanical ventilation and prolonging hospital stay<sup>27</sup>. Though anticoagulation has a well-established role for prophylaxis of noninfective pulmonary embolism<sup>28</sup>, it is not used for active treatment of septic pulmonary emboli due to the increased bleeding risk in area of the infected emboli<sup>5</sup>. Nevertheless, treatment of septic pulmonary emboli using anticoagulation has been described in small cohort studies<sup>29, 30</sup>. Further research on the potential effects of warfarin on vegetation size and thromboembolic complications and the prognostic implications of any such effect is warranted.

The use of antiplatelet therapy in reducing mortality or embolic risk in IE is similarly controversial. In a retrospective cohort study of 600 IE patients, patients with prior use of aspirin, dipyridamole, clopidogrel or ticlopidine had a lower risk of stroke compared to control, but not significantly different mortality<sup>31</sup>. In a randomized controlled trial of 115 IE patients, treatment with aspirin 325mg/day did not significantly reduce the risk of embolic stroke nor in-hospital mortality, instead increasing the risk of bleeding<sup>32</sup>; also, this trial excluded patients with previous antiplatelet use, similar to our study. Interestingly, low-dose aspirin, compared to high-dose aspirin, was more effective at reducing bacterial density and vegetation weight<sup>33</sup>. Furthermore, a recent cohort study involving 34 IE patients compared long term use of antiplatelets or anticoagulants and patients without the use of either medication class. Embolic

events occurred in 30% of patients receiving treatment and 7.1% not receiving treatment, with similar mortality risk between both groups<sup>34</sup>. The study found a lower number of bleeding events in the group without antiplatelet/anticoagulant use, in agreement with the subgroup analysis in the current study where patients who received heparin within 14 days of IE diagnosis were excluded. In local clinical practice, the vast majority of admitted IE patients are started on warfarin instead of DOACs due to valvular nature of the disease; therefore, it was not possible to conduct separate analyses investigating DOAC use on the study outcomes. It remains to be elucidated whether or not DOACs are similarly associated with a decreased risk of mortality in the context of IE. Overall, there is a lack of consensus on the role of antithrombotics in general in the management of IE, be it anticoagulants or antiplatelets, and the use of systemic antibiotics remains the preferred strategy to reduce the risks of mortality and septic embolization<sup>11, 35, 36</sup>.

Previous evidence on anticoagulation in IE is mostly based on case reports or non-representative observational studies, which were limited by small sample sizes and sampling bias. Nonetheless, a placebo-controlled trial on this study topic is difficult to organize given the potential risk of bleeding in warfarin use. The present study attempted to minimize indication bias for warfarin prescription by propensity score matching with potential confounders such as prosthetic valve replacement, CHA<sub>2</sub>DS<sub>2</sub>-VASc score and atrial fibrillation. The population-based nature of the study also meant that the results are widely generalizable, at least to other developed Asian cities. Moreover, we performed a number of subgroup and sensitivity analyses to ensure robustness of our analyses, observing mostly consistent findings in patients who did not receive cardiac surgery or heparin, and in both patients with early and late warfarin use. The subgroup analysis of patients who did not receive cardiac surgery was especially important, as the implantation of mechanical prosthetic valves could have been the primary indication of warfarin in some patients. By demonstrating consistent results in patients



who did not receive cardiac surgery, the associations between warfarin use and lower mortality risk was likely to be explained by factors other than warfarin being a surrogate for surgical treatment. Nonetheless, it must be stressed that clinicians should be aware that warfarin use was likely associated with higher risk of intracranial haemorrhage, as shown in the two *post hoc* subgroup analyses of patients and in the competing risk regression. Although mortality benefit was shown despite such detrimental associations with bleeding risks, more work is needed to carefully delineate the risk-benefit balance in using warfarin in patients with IE, especially with the consideration of morbidity in addition to mortality, before more definitive recommendations can be made for clinical practice.

### *Limitations*

The present study has several limitations. First, there was incomplete baseline INR data of patients within the treatment group and the coagulability status of study patients before initiation on warfarin is unknown. This was addressed by excluding patients with use of anticoagulants within 30 days before IE diagnosis in both treatment groups. Second, this study did not account for the treatment duration, interruption or discontinuation of therapy in warfarin users, which may influence ischemic stroke or mortality risk. Major bleeding events such as intracranial hemorrhage and gastrointestinal bleeding may prompt interruption of anticoagulant therapy<sup>11</sup>, which, if abrupt, may lead to a sharp drop in INR<sup>37</sup>, in turn increasing the risk of ischemic stroke. Third, this was an observational study; owing to limitations of the CDARS database, echocardiographic findings such as the size of vegetation, valvular destruction, and perivalvar abscesses were not coded in the system and therefore could not be explored. Fourth, although a number of baseline characteristics were used for propensity score matching, the observational nature of this study meant that unobserved and residual confounders cannot be

completely eliminated. Nonetheless, we believe the baseline characteristics considered should be pragmatically sufficient as a representation of the overall comorbid status of the included patients. Lastly, as all diagnoses and outcomes were ascertained using ICD codes, miscoding may be possible. Nonetheless, CDARS and the linked Hong Kong Death Registry have been used extensively in peer-reviewed studies<sup>38-40</sup>, and all coding were performed by clinicians independent of the authors.

## Conclusions

In patients with IE, warfarin use may be associated with decreased risks of mortality compared with non-use of warfarin, with a non-significant difference in the risk of ischaemic stroke and a higher risk of intracranial haemorrhage. Larger studies are warranted to confirm these findings and delineate the underlying mechanisms.

**Acknowledgements:** None.

**Sources of Funding:** None.

**Disclosures:** None.

## Supplemental Material

Tables S1-S3

Figures S1-S6

## References

1. Rajani R, Klein JL. Infective endocarditis: A contemporary update. *Clin Med (Lond)*. 2020;20:31-35
2. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: Three successive population-based surveys. *J Am Coll Cardiol*. 2012;59:1968-1976
3. Mostaghim AS, Lo HYA, Khardori N. A retrospective epidemiologic study to define risk factors, microbiology, and clinical outcomes of infective endocarditis in a large tertiary-care teaching hospital. *SAGE Open Med*. 2017;5:2050312117741772
4. Hu W, Wang X, Su G. Infective endocarditis complicated by embolic events: Pathogenesis and predictors. *Clin Cardiol*. 2021;44:307-315
5. Mohananey D, Mohadjer A, Pettersson G, Navia J, Gordon S, Shrestha N, et al. Association of vegetation size with embolic risk in patients with infective endocarditis: A systematic review and meta-analysis. *JAMA Intern Med*. 2018;178:502-510
6. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG, Jr., Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The international collaboration on endocarditis-prospective cohort study. *Arch Intern Med*. 2009;169:463-473
7. Garcia-Cabrera E, Fernandez-Hidalgo N, Almirante B, Ivanova-Georgieva R, Nouredine M, Plata A, et al. Neurological complications of infective endocarditis: Risk factors, outcome, and impact of cardiac surgery: A multicenter observational study. *Circulation*. 2013;127:2272-2284

8. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: A 17-year experience in a teaching hospital in finland. *Arch Intern Med*. 2000;160:2781-2787
9. Thiene G, Basso C. Pathology and pathogenesis of infective endocarditis in native heart valves. *Cardiovasc Pathol*. 2006;15:256-263
10. Holland TL, Baddour LM, Bayer AS, Hoen B, Miro JM, Fowler VG, Jr. Infective endocarditis. *Nat Rev Dis Primers*. 2016;2:16059
11. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 esc guidelines for the management of infective endocarditis: The task force for the management of infective endocarditis of the european society of cardiology (esc). Endorsed by: European association for cardio-thoracic surgery (eacts), the european association of nuclear medicine (eanm). *Eur Heart J*. 2015;36:3075-3128
12. Lerche CJ, Christophersen LJ, Goetze JP, Nielsen PR, Thomsen K, Enevold C, et al. Adjunctive dabigatran therapy improves outcome of experimental left-sided staphylococcus aureus endocarditis. *PLoS One*. 2019;14:e0215333
13. Hook EW, 3rd, Sande MA. Role of the vegetation in experimental streptococcus viridans endocarditis. *Infect Immun*. 1974;10:1433-1438
14. Veloso TR, Que YA, Chaouch A, Giddey M, Vouillamoz J, Rousson V, et al. Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: A role for long-term prevention of infective endocarditis in humans? *J Infect Dis*. 2015;211:72-79
15. Slivka AP, Agriesti JE, Orsinelli DA. Natural history of nonbacterial thrombotic endocarditis treated with warfarin. *Int J Stroke*. 2021;16:519-525

16. Lee SJ, Oh SS, Lim DS, Hong SK, Choi RK, Park JS. Usefulness of anticoagulant therapy in the prevention of embolic complications in patients with acute infective endocarditis. *Biomed Res Int*. 2014;2014:254187
17. Sawant AC, Kumar A, McCray W, Tetewsky S, Parone L, Sridhara S, et al. Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: A national veterans affairs database study. *J Geriatr Cardiol*. 2019;16:706-709
18. Salaun E, Touil A, Hubert S, Casalta JP, Gouriet F, Robinet-Borgomano E, et al. Intracranial haemorrhage in infective endocarditis. *Arch Cardiovasc Dis*. 2018;111:712-721
19. Wai AK, Chan CY, Cheung AW, Wang K, Chan SC, Lee TT, et al. Association of molnupiravir and nirmatrelvir-ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate covid-19. *Lancet Reg Health West Pac*. 2023;30:100602
20. Lee TTL, Hui JMH, Lee YHA, Satti DI, Shum YKL, Kiu PTH, et al. Sulfonylurea is associated with higher risks of ventricular arrhythmia or sudden cardiac death compared with metformin: A population-based cohort study. *J Am Heart Assoc*. 2022;11:e026289
21. Zhou J, Lee S, Liu X, Iltaf Satti D, Tai Loy Lee T, Hou In Chou O, et al. Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses. *Bone*. 2022;156:116303
22. Zhou J, Leung KSK, Kong D, Lee S, Liu T, Wai AKC, et al. Low rates of liver injury in edoxaban users: Evidence from a territory-wide observational cohort study. *Clin Cardiol*. 2021;44:886-889


23. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. *Pharm Stat.* 2011;10:150-161
24. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. Warfarin therapy and incidence of cerebrovascular complications in left-sided native valve endocarditis. *Eur J Clin Microbiol Infect Dis.* 2011;30:151-157
25. Rasmussen RV, Snygg-Martin U, Olaison L, Buchholtz K, Larsen CT, Hassager C, et al. Major cerebral events in staphylococcus aureus infective endocarditis: Is anticoagulant therapy safe? *Cardiology.* 2009;114:284-291
26. Galzerano D, Pergola V, Kinsara AJ, Vriza O, Elmahi I, Al Sergani A, et al. Right-sided infective endocarditis and pulmonary embolism: A multicenter study. *Monaldi Arch Chest Dis.* 2022;92
27. Elsaghir H, Al Khalili Y. Septic emboli. *Statpearls.* Treasure Island (FL); 2022.
28. Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: A review. *JAMA.* 2022;328:1336-1345
29. Song XY, Li S, Cao J, Xu K, Huang H, Xu ZJ. Cardiac septic pulmonary embolism: A retrospective analysis of 20 cases in a chinese population. *Medicine (Baltimore).* 2016;95:e3846
30. Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN. Associations and outcomes of septic pulmonary embolism. *Open Respir Med J.* 2014;8:28-33
31. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. *Clin Infect Dis.* 2007;44:1180-1186

32. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. *J Am Coll Cardiol*. 2003;42:775-780
33. Nicolau DP, Freeman CD, Nightingale CH, Quintiliani R, Coe CJ, Maderazo EG, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. *Infect Immun*. 1993;61:1593-1595
34. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: An analysis from the ice prospective cohort study (ice-pcs). *Am Heart J*. 2007;154:1086-1094
35. Pathickal SM, Park TE, Sharma R. Clinical outcomes associated with the use of anticoagulant and antiplatelet agents in patients undergoing treatment for infective endocarditis: A pilot study. *Clin Ther*. 2020;42:1828-1838
36. Davenport J, Hart RG. Prosthetic valve endocarditis 1976-1987. Antibiotics, anticoagulation, and stroke. *Stroke*. 1990;21:993-999
37. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: Changes in the international normalized ratio. *Ann Intern Med*. 1995;122:40-42
38. Chan JSK, Lakhani I, Lee TTL, Chou OHI, Lee YHA, Cheung YM, Yeung HW, Tang P, Ng K, Dee EC, Liu T, Wong WT, Tse G, Leung FP. Cardiovascular outcomes and hospitalizations in Asian patients receiving immune checkpoint inhibitors: a population-based study. *Curr Probl Cardiol*. 2023; 48(1): 101380.
39. Li X, Chan JSK, Guan B, Peng S, Wu X, Lu X, Zhou J, Hui JMH, Lee YHA, Satti DI, Tsang SL, Wu S, Chen S, Tse G, Liu S. Triglyceride-glucose index and the

538 risk of heart failure: evidence from two large cohorts and a Mendelian  
539 randomization analysis. *Cardiovasc Diabetol.* 2022; 21(1): 229.  
540 40. Lee YHA, Zhou J, Hui JMH, Liu X, Lee TTL, Hui K, Chan JSK, Wai AKC,  
541 Wong WT, Liu T, Ng K, Lee S, Dee EC, Zhang Q, Tse G. Risk of new-onset  
542 prostate cancer for metformin versus sulphonylurea use in type 2 diabetes  
543 mellitus: a propensity score-matched study. *J Natl Compr Cancer Netw.* 2022;  
544 20(6): 674-682.e15.  
545



**Figure 1: Study flow chart**



**Table 1: Characteristics of patients with infective endocarditis before and after 1:1 propensity score matching**

Characteristics	Before matching		After matching			
	Warfarin use (N=734)	No warfarin use (N=4743)	Warfarin use (N=675)	No warfarin use (N=675)	SMD	VR
<b>Demographics</b>						
Male, N (%)	416 (56.7)	3156 (66.5)	385 (57.0)	361 (53.5)	0.04	-
Baseline age, years	59.63±15.89	58.12±19.64	59.36±16.25	61.45±18.74	0.13	0.75
<b>Comorbidities</b>						
Charlson Comorbidity Index	2.44±2.27	2.08±2.39	2.37±2.29	2.51±2.38	0.06	0.93
Hypertension, N (%)	137 (18.7)	828 (17.5)	126 (18.7)	137 (20.3)	0.02	-
Atrial fibrillation, N (%)	253 (34.5)	329 (6.9)	206 (30.5)	213 (31.6)	0.01	-
Heart failure, N(%)	229 (31.2)	522 (11.0)	187 (27.7)	202 (29.9)	0.02	-
Diabetes mellitus, N (%)	83 (11.3)	545 (11.5)	78 (11.6)	85 (12.6)	0.01	-
Intracranial hemorrhage, N (%)	25 (3.4)	108 (2.3)	21 (3.1)	24 (3.6)	<0.01	-
Chronic kidney disease, N (%)	28 (3.8)	295 (6.2)	28 (4.1)	25 (3.7)	<0.01	-
Vascular disease, N (%)	8 (1.1)	36 (0.8)	6 (0.9)	7 (1.0)	<0.01	-
Valvular replacement, N (%)	107 (14.6)	43 (0.9)	52 (7.7)	39 (5.8)	0.02	-
<b>Medications</b>						
ACE inhibitors, N (%)	151 (20.6)	473 (10.0)	130 (19.3)	147 (21.8)	0.02	-
Angiotensin receptor blockers, N (%)	38 (5.2)	124 (2.6)	33 (4.9)	32 (4.7)	<0.01	-
Beta blockers, N (%)	149 (20.3)	510 (10.8)	132 (19.6)	135 (20.0)	<0.01	-
NSAIDs, N (%)	168 (22.9)	847 (17.9)	157 (23.3)	170 (25.2)	0.02	-
H2 receptor antagonists, N (%)	147 (20.0)	664 (14.0)	131 (19.4)	138 (20.4)	0.01	-
Proton pump inhibitors, N (%)	136 (18.5)	600 (12.7)	116 (17.2)	118 (17.5)	<0.01	-
Selective serotonin reuptake inhibitors, N (%)	8 (1.1)	47 (1.0)	8 (1.2)	6 (0.9)	<0.01	-
<b>Blood culture results</b>						
Staphylococci, N (%)	87 (11.9)	1023 (21.6)	73 (10.8)	69 (10.2)	<0.01	-
Streptococci, N (%)	68 (9.3)	681 (14.4)	58 (8.6)	52 (7.7)	<0.01	-
Enterococci, N (%)	12 (1.6)	112 (2.4)	8 (1.2)	11 (1.6)	<0.01	-
HACEK group, N (%)	1 (0.1)	33 (0.7)	1 (0.1)	3 (0.4)	<0.01	-
<b>Outcomes</b>						
Ischemic stroke, N (%)	57 (7.8)	314 (6.6)	52 (7.7)	50 (7.4)	-	-
All-cause mortality, N (%)	93 (12.7)	1246 (26.3)	83 (12.3)	193 (28.6)	-	-

Intracranial hemorrhage, N (%)	39 (5.3)	184 (3.9)	36 (5.3)	29 (4.3)	-	-
Gastrointestinal bleeding, N (%)	30 (4.1)	146 (3.1)	27 (4.0)	26 (3.9)	-	-
<b><i>Treatments received within 14 days after IE diagnosis</i></b>						
Direct oral anticoagulants, N (%)	13 (1.8)	47 (1.0)	13 (1.9)	23 (3.4)	-	-
Heparin, N (%)	466 (63.5)	368 (7.8)	435 (64.4)	68 (10.1)	-	-
Cardiac surgery, N (%)	171 (23.3)	453 (9.6)	162 (24.0)	59 (8.7)	-	-

551 Continuous variables were expressed as mean  $\pm$  standard deviation. SMD and VR were only displayed for  
552 variables considered in propensity score matching. SMD <0.1 / VR >0.5 & 2.0 indicated good balance in  
553 matching.

554 ACE, Angiotensin-converting enzyme; IE: Infective endocarditis; NSAID: Nonsteroidal anti-inflammatory  
555 drugs; SMD: Standardized mean difference; VR: Variance ratio.

**Table 2: Main and subgroup analyses of study outcomes**

Patient group	Outcomes	30-day risk Hazard ratio (95% CI)	90-day risk Hazard ratio (95% CI)
All patients	Ischemic stroke	0.87 (0.53-1.43)	1.04 (0.70-1.53)
	All-cause mortality	0.41 (0.28-0.58)	0.50 (0.39-0.65)
	Intracranial hemorrhage	1.57 (0.80-3.07)	1.25 (0.77-2.04)
	Gastrointestinal bleeding	0.86 (0.41-1.81)	1.04 (0.60-1.78)
Patients who did not receive heparin within 14 days of infective endocarditis diagnosis	Ischemic stroke	0.89 (0.36-2.20)	1.28 (0.64-2.58)
	All-cause mortality	0.52 (0.32-0.84)	0.59 (0.40-0.86)
	Intracranial hemorrhage	2.54 (0.98-6.54)	2.56 (1.13-5.81)
	Gastrointestinal bleeding	1.67 (0.40-6.98)	0.90 (0.37-2.23)
Patients who did not receive cardiac surgery within 14 days of infective endocarditis diagnosis	Ischemic stroke	1.37 (0.76-2.48)	1.61 (1.00-2.61)
	All-cause mortality	0.35 (0.22-0.54)	0.47 (0.35-0.64)
	Intracranial hemorrhage	1.71 (0.78-3.73)	1.89 (1.01-3.53)
	Gastrointestinal bleeding	1.22 (0.51-2.95)	1.34 (0.73-2.47)

CI: Confidence interval. HR: Hazard ratio.


**Table 3: Results of sensitivity analyses**

Analysis done	Outcomes	30-day	90-day
	Ischemic stroke	0.64 (0.37-1.11) <sup>1</sup>	0.81 (0.54-1.25) <sup>1</sup>
Restricting to patients who had warfarin initiated within seven days of infective endocarditis diagnosis	All-cause mortality	0.48 (0.33-0.71) <sup>1</sup>	0.51 (0.38-0.67) <sup>1</sup>
	Intracranial hemorrhage	1.00 (0.51-1.96) <sup>1</sup>	0.75 (0.45-1.26) <sup>1</sup>
	Gastrointestinal bleeding	0.52 (0.22-1.23) <sup>1</sup>	0.56 (0.30-1.03) <sup>1</sup>
Fine-Gray competing risk regression with all-cause mortality as competing event	Ischemic stroke	0.95 (0.55-1.65) <sup>2</sup>	1.11 (0.74-1.68) <sup>2</sup>
	Intracranial hemorrhage	3.34 (1.34-8.31) <sup>2</sup>	1.63 (0.95-2.81) <sup>2</sup>
	Gastrointestinal bleeding	0.99 (0.41-2.39) <sup>2</sup>	1.14 (0.63-2.05) <sup>2</sup>

<sup>1</sup> Hazard ratio and 95% confidence intervals

<sup>2</sup> Sub-hazard ratio and 95% confidence intervals

588 **Figure 2: Kaplan-Meier curves of cumulative freedom from the study outcomes,**  
 589 **stratified by warfarin use. CI, confidence interval. HR, hazard ratio**  
 590



591

**Figure 3: Kaplan-Meier survival curves of study outcomes, stratified by the timing of warfarin initiation.** CI, confidence interval. HR, hazard ratio.

